News & Insights

Stay informed with transaction announcements, firm news, and strategic insights from D. Boral Capital.

News & Insights

Published by D. Boral Capital

D. Boral Capital Acted as Exclusive Placement Agent to Trio-Tech International (NYSE: TRT) in Connection with its ~$10,000,000 Registered Direct Offering

D. Boral Capital Acted as Exclusive Placement Agent to Trio-Tech International (NYSE: TRT) in Connection with its ~$10,000,000 Registered Direct Offering

Read More →
D. Boral Capital Acted as Exclusive Placement Agent to Genius Group Limited (NYSE: GNS) in Connection with its $8,000,000 Registered Direct Offering

D. Boral Capital Acted as Exclusive Placement Agent to Genius Group Limited (NYSE: GNS) in Connection with its $8,000,000 Registered Direct Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to Maywood Acquisition Corp. 2 (NASDAQ: MYXXU) in Connection with its $100,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to Maywood Acquisition Corp. 2 (NASDAQ: MYXXU) in Connection with its $100,000,000 Initial Public Offering

Read More →
Breakthrough in Neuropsychiatry: Stabilized D-Cycloserine the Future of TMS Augmentation with the CMIO of NRx Pharmaceuticals

Breakthrough in Neuropsychiatry: Stabilized D-Cycloserine the Future of TMS Augmentation with the CMIO of NRx Pharmaceuticals

Read More →
D. Boral Capital Acted as Sole Bookrunner to Future Money Acquisition Corporation (NASDAQ: FMACU) in Connection with its $112,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to Future Money Acquisition Corporation (NASDAQ: FMACU) in Connection with its $112,000,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to Pono Capital Four, Inc. (Nasdaq: PONOU) in Connection with its $120,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to Pono Capital Four, Inc. (Nasdaq: PONOU) in Connection with its $120,000,000 Initial Public Offering

Read More →
Citius Pharmaceuticals: From Development Stage to Commercial Oncology

Citius Pharmaceuticals: From Development Stage to Commercial Oncology

Read More →
D. Boral Capital Acted as Sole Bookrunner to ClearThink 1 Acquisition Corp. (Nasdaq: CTAAU) in Connection with its ~$125,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to ClearThink 1 Acquisition Corp. (Nasdaq: CTAAU) in Connection with its ~$125,000,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to D. Boral Acquisition I Corp. (Nasdaq: DBCAU) in Connection with its $287,500,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to D. Boral Acquisition I Corp. (Nasdaq: DBCAU) in Connection with its $287,500,000 Initial Public Offering

Read More →
Advancing Acute Psychiatric Care: Ketamine, Suicide Prevention, and a National Treatment Platform at NRx Pharmaceuticals

Advancing Acute Psychiatric Care: Ketamine, Suicide Prevention, and a National Treatment Platform at NRx Pharmaceuticals

Read More →
D. Boral Capital Acted as Lead Placement Agent to Neo-Concept International Group Holdings Limited (Nasdaq: NCI) in Connection with its ~$8,000,000 Follow-On Offering

D. Boral Capital Acted as Lead Placement Agent to Neo-Concept International Group Holdings Limited (Nasdaq: NCI) in Connection with its ~$8,000,000 Follow-On Offering

Read More →
D. Boral Capital Acted as Co-Manager to Dakota Gold Corp. (NYSE: DC) in Connection with its $75,000,000 Follow-On Offering

D. Boral Capital Acted as Co-Manager to Dakota Gold Corp. (NYSE: DC) in Connection with its $75,000,000 Follow-On Offering

Read More →